Business Description
Oxford BioDynamics PLC
ISIN : GB00BD5H8572
Total Employee Number:
51Description
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 4.58 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -13.11 | |||||
Beneish M-Score | -4.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 51.7 | |||||
3-Year EPS without NRI Growth Rate | 50.8 | |||||
3-Year FCF Growth Rate | 53.8 | |||||
3-Year Book Growth Rate | -66.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.37 | |||||
9-Day RSI | 46.85 | |||||
14-Day RSI | 47.93 | |||||
6-1 Month Momentum % | -83.33 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.88 | |||||
Quick Ratio | 0.8 | |||||
Cash Ratio | 0.53 | |||||
Days Inventory | 170.93 | |||||
Days Sales Outstanding | 180.44 | |||||
Days Payable | 692.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -169.2 | |||||
Shareholder Yield % | -155.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.67 | |||||
Operating Margin % | -981.46 | |||||
Net Margin % | -1018.54 | |||||
EBITDA Margin % | -905.3 | |||||
FCF Margin % | -716.47 | |||||
OCF Margin % | -694.02 | |||||
ROE % | -293.45 | |||||
ROA % | -99.89 | |||||
ROIC % | -134.1 | |||||
3-Year ROIIC % | 92.72 | |||||
ROC (Joel Greenblatt) % | -204.62 | |||||
ROCE % | -129.44 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1 | |||||
PB Ratio | 1 | |||||
EV-to-EBIT | -0.72 | |||||
EV-to-EBITDA | -0.81 | |||||
EV-to-Revenue | 7.32 | |||||
EV-to-Forward-Revenue | 2.59 | |||||
EV-to-FCF | -1.02 | |||||
Price-to-GF-Value | 0.05 | |||||
Earnings Yield (Greenblatt) % | -138.89 | |||||
FCF Yield % | -182.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oxford BioDynamics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.287 | ||
| EPS (TTM) (€) | -0.011 | ||
| Beta | -6.0807 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 260.68 | ||
| 14-Day RSI | 47.93 | ||
| 14-Day ATR (€) | 0.00133 | ||
| 20-Day SMA (€) | 0.001025 | ||
| 12-1 Month Momentum % | -50 | ||
| 52-Week Range (€) | 0.0005 - 0.0135 | ||
| Shares Outstanding (Mil) | 4,290.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oxford BioDynamics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oxford BioDynamics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-22 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-16 | In 168 days | ||
| Second quarter earnings results for 2026 | 2026-06-30 | 0.00 (+800.00%) | ||
| General meeting for 2025 | 2026-01-26 10:00 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2025-12-22 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-16 | 0.00 (+100.00%) | ||
| Second quarter earnings results for 2025 | 2025-06-30 | 0.00 (+0.00%) | ||
| General meeting for 2024 | 2025-03-28 10:00 | 0.00 (+0.00%) | ||
| Annual report for 2024 | 2025-03-05 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-02-28 | 0.00 (+0.00%) |
Show
Entries
Oxford BioDynamics PLC Frequently Asked Questions
What is Oxford BioDynamics PLC(FRA:LMQ)'s stock price today?
The current price of FRA:LMQ is €0.00. The 52 week high of FRA:LMQ is €0.01 and 52 week low is €0.00.
When is next earnings date of Oxford BioDynamics PLC(FRA:LMQ)?
The next earnings date of Oxford BioDynamics PLC(FRA:LMQ) is 2026-12-16 Est..
Does Oxford BioDynamics PLC(FRA:LMQ) pay dividends? If so, how much?
Oxford BioDynamics PLC(FRA:LMQ) does not pay dividend.
Press Release
Articles on Oxford BioDynamics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers